Status: Recruiting
Pharmacogenetic Panel to Prevent Adverse Drug Reactions in Daily Primary Care Practice:
The purpose of this study is to determine whether the implementation of pre-emptive pharmacogenomic (PGx) testing of a panel of clinically relevant PGx markers, to guide the dose and drug selection for 39 commonly prescribed drugs, will result in an overall reduction in the number of clinically relevant drug-genotype associated ADRs which are causally related to the initial drug of inclusion (referred to as 'index drug').
Participants needed: 66
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Oct 14, 2025Locations: 1
Eligibility criteria
Subject must be ≥ 18 years old [+5]
For the investigational arm only: Previous (direct-to-consumer, or clinical) pha... [+13]